Physician profile
Ryan Welter
NPI 1124198502
$2,173.13
in general payments reported to CMS, 2019-2025
23 companies · $224 in 2025
The $224 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2020: $33.41 · 2021: $197 · 2022: $276 · 2023: $403 · 2024: $812 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,439.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $368.85 | 2021-2025 | Rinvoq |
| Arcutis Biotherapeutics, INC. | $254.61 | 2024 | Zoryve |
| Merz North America, INC. | $252.21 | 2022-2023 | |
| Revance Therapeutics, INC. | $180.30 | 2024-2025 | Daxxify |
| Glaxosmithkline, LLC. | $176.82 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $127.00 | 2024 | Sotyktu |
| Paratek Pharmaceuticals, INC. | $124.97 | 2024 | Nuzyra |
| Vanda Pharmaceuticals INC. | $118.70 | 2022-2023 | Hetlioz |
| Novo Nordisk INC | $100.64 | 2020-2023 | Ozempic, Rybelsus |
| Arteriocyte Medical Systems, INC. | $85.17 | 2023 | Magellan |
| Incyte Corporation | $66.53 | 2024 | Opzelura |
| Ucb, INC. | $54.13 | 2021 | |
| Pfizer INC. | $46.05 | 2019 | |
| Sanofi-Aventis U.S. LLC | $36.84 | 2019-2021 | |
| Biofrontera INC. | $36.62 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $33.64 | 2021-2025 | Ebglyss |
| Astrazeneca Pharmaceuticals Lp | $22.35 | 2019 | |
| Vbi Vaccine (Delaware) INC. | $20.27 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $19.90 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.71 | 2022 | |
| Solta Medical, A Division of Bausch Health US, LLC | $15.31 | 2025 | Clear & Brilliant |
| Alkermes, INC. | $14.51 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Welter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.